This page contains a Flash digital edition of a book.
Indication Erivedge®


(vismodegib) capsule is a prescription


medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation.


Important Safety Information


What is the most important information I should know about Erivedge?


• Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects


I know it’s time to act I hoped it wouldn’t grow I hoped it wouldn’t come back


• For females who can become pregnant, talk with your healthcare provider about the risks of Erivedge to your unborn child. Your healthcare provider should do a pregnancy test within 7 days before you start taking Erivedge to fi nd out if you are pregnant. Avoid pregnancy by using highly effective birth control before starting Erivedge, and continue during treatment and for 7 months after your last dose. Tell your healthcare provider right away if you have unprotected sex or think that your birth control has failed


• For males, always use a condom with a spermicide during sex with female partners while you are taking Erivedge and for 2 months after your last dose, even if you have had a vasectomy


• Tell your healthcare provider right away if you or your female partner could be pregnant or thinks she is pregnant while you are taking Erivedge


• Before taking Erivedge, tell your healthcare provider if you are pregnant or plan to become pregnant, or if you are breast-feeding or plan to breast-feed


Exposure to Erivedge during pregnancy: Pregnant women are encouraged to participate in a program that collects information about exposure and the effects on the mother and her unborn child by calling the Genentech Adverse Event Line at (888) 835-2555.


What should I avoid while taking Erivedge? Do not give blood or blood products during treatment with Erivedge and for 7 months after your last dose.


Talk to your dermatologist — it’s not too late to give your advanced basal cell carcinoma some serious attention.


SEND IN THE ATTACHED CARD TO GET


AN ERIVEDGE INFORMATION PACKET You can also call (855) 7-ERIVEDGE (855-737-4833) or visit Erivedgesupport.com.


Please see the accompanying Medication Guide on the next page for additional important safety information.


If you don’t have prescription coverage or can’t afford your medicine, we may be able to help. Visit genentech-access.com/erivedge/patients or call (888) 249-4918 to learn more. Capsule shown not actual size.


© 2013 Genentech USA, Inc. All rights reserved. HED0001784501 Printed in USA.


What are the possible side effects of Erivedge? The most common side effects of Erivedge are:


• Muscle spasms • Hair loss • Change in how things taste or loss of taste • Weight loss • Tiredness


• Nausea • Diarrhea


• Decreased appetite • Constipation • Vomiting • Joint aches


These are not all of the possible side effects of Erivedge, and it is not possible to predict what side effects you will have or how severe they may be. For more information, ask your healthcare provider or pharmacist.


You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.


Please see the full Prescribing Information, including serious side effects, at Erivedge.com.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124